Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BT-GSI, a γ-secretase inhibitor (GSI) with bone-targeting capabilities, effectively inhibits Notch signaling. Exhibiting dual action, it possesses both anti-myeloma and anti-resorptive properties, making it a promising candidate for research into multiple myeloma and related bone diseases. Additionally, BT-GSI demonstrates potential in inhibiting tumor growth and the progression of osteolytic disease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,970.00 | |
50 mg | 8-10 weeks | $ 2,580.00 | |
100 mg | 8-10 weeks | $ 3,400.00 |
Description | BT-GSI, a γ-secretase inhibitor (GSI) with bone-targeting capabilities, effectively inhibits Notch signaling. Exhibiting dual action, it possesses both anti-myeloma and anti-resorptive properties, making it a promising candidate for research into multiple myeloma and related bone diseases. Additionally, BT-GSI demonstrates potential in inhibiting tumor growth and the progression of osteolytic disease. |
Molecular Weight | 730.52 |
Formula | C26H46BrN5O10P2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.